Related Experiment Video
Updated: May 3, 2026
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Macrovipera lebetinus obtusa Venom and Its Fractions Affect Human Dermal Microvascular Endothelial and Fibrosarcoma
Narine Ghazaryan1, Lars Van Werven2, Thomas Liepold2
1Orbeli Institute of Physiology of NAS RA, Yerevan 0028, Armenia.
Abstract:
The venom of Macrovipera lebetinus obtusa (MLO) has remarkable properties that are hard to overlook. This venom's described 38 protein components work synergistically, forming complexes that greatly enhance their combined effectiveness. Previous studies have shown that both crude venom and one of its components, obtustatin, can reduce sarcoma tumors by 50% and 30%, respectively. Obtustatin, a member of the short disintegrin family, inhibits the angiogenic activity of α1β1 integrin, the adhesive receptor of collagen IV. However, the mechanisms of the greater efficacy of the crude venom compared to its isolated components remain unclear. To investigate this, we propose an experimental work to explore the activity of certain low-molecular-weight components of MLO venom. Our in vitro tests on fibrosarcoma (HT-1080) cells using six venom fractions revealed cytotoxic fractions, which, through mass spectrometry, were identified as containing protein classes such as dimeric and short disintegrins, acidic phospholipase A2, and serine proteinases. Notably, these fractions exhibited minimal toxicity to human dermal microvascular endothelial (HDEC) cells, suggesting their potential as a promising candidate for oncotherapy in the future.
Insights
Macrovipera lebetinus obtusa (MLO) venom components show promise for cancer therapy. Specific fractions effectively target fibrosarcoma cells with low toxicity to healthy cells, suggesting potential oncotherapy applications.
Area of Science:
- * Biochemistry and Molecular Biology
- * Oncology and Pharmacology
Background:
- * The venom of *Macrovipera lebetinus obtusa* (MLO) contains synergistic protein components with demonstrated anti-tumor effects.
- * While obtustatin, a MLO venom component, inhibits angiogenesis, the mechanisms behind the crude venom's superior efficacy remain unclear.
- * Understanding the synergistic interactions of MLO venom components is crucial for developing novel cancer therapeutics.
Purpose of the Study:
- * To investigate the cytotoxic activity of low-molecular-weight components within MLO venom against fibrosarcoma cells.
- * To identify the protein classes present in cytotoxic venom fractions.
- * To assess the selective toxicity of these fractions towards cancer cells versus normal endothelial cells.
Main Methods:
- * In vitro testing of six MLO venom fractions on fibrosarcoma (HT-1080) cells.
- * Mass spectrometry analysis to identify protein components within active fractions.
- * Cytotoxicity assays using human dermal microvascular endothelial (HDEC) cells to evaluate selectivity.
Main Results:
- * Several MLO venom fractions exhibited significant cytotoxic effects on fibrosarcoma cells.
- * Identified protein classes in active fractions include dimeric and short disintegrins, acidic phospholipase A2, and serine proteinases.
- * These fractions demonstrated minimal toxicity to human dermal microvascular endothelial cells.
Conclusions:
- * Specific low-molecular-weight components of MLO venom possess potent and selective anti-cancer activity.
- * The identified protein classes are key contributors to the venom's cytotoxic effects.
- * These findings highlight the potential of MLO venom fractions as candidates for future oncotherapy development.
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
